nogapendekin alfa inbakicept
nogapendekin alfa inbakicept: developed by 1 company · 28 clinical trials tracked.
nogapendekin alfa inbakicept evidence translation
What we can confirm
28 tracked trials
What it means
What to watch
Prepared research question
How could nogapendekin alfa inbakicept → IBRX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Development Pipeline (2)
| Company | Phase |
|---|---|
| ImmunityBio, Inc. (IBRX) Pancreatic Cancer; NSCLC Stage IV; Bladder Cancer | Phase 3 |
| ImmunityBio, Inc. (IBRX) | Phase 3 |
Clinical Trials (28)showing 10 most recent
ResQ117EX-ALC: Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy
A Phase Ib Study Evaluating the Safety and Tolerability of Sipuleucel-T (Sip-T) in Combination With N-803 in Patients With Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
Primary endpoint: Frequency of dose-limiting toxicities (Cohort 1 only)
Phase 1b/2, Open-Label Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbakicept (NAI) Plus Standard of Care in Critically Ill Adults With Sepsis
Primary endpoint: 28-Day Survival Rate
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Open-Label, Single-Arm Phase 2 Study Of Nogapendekin Alfa Inbakicept, PD-L1 T-HaNK, And Bevacizumab And Randomized Phase 2B Study Of Nogapendekin Alfa Inbakicept, Bevacizumab, And Tumor Treatment Fields With Or Without PD-L1 T-HaNK In Participants With Recurrent Or Progressive Glioblastoma
Primary endpoint: Progression-Free Survival (PFS)
A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)
Primary endpoint: Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants)
Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combination With Standard of Care Versus Standard of Care Alone in Critically Ill Adults With Sepsis and Persistent Lymphopenia
Primary endpoint: 28-day all-cause mortality rate
Phase 3 Randomized, Blinded, Placebo-Controlled Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells In Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress Syndrome
Primary endpoint: 28-day all-cause mortality
Open-Label, Phase 2 Chemotherapy-Free Study of CD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma
Primary endpoint: ORR in accordance with Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC)
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Primary endpoint: Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide ISA-51 VG adjuvant in combination with N-803
Frequently asked questions
Who is developing nogapendekin alfa inbakicept?
nogapendekin alfa inbakicept is being developed by ImmunityBio, Inc..
How many clinical trials involve nogapendekin alfa inbakicept?
BioSniper tracks 28 clinical trials involving nogapendekin alfa inbakicept.